Amarin Corp Plc (AMRN)

[ziploc_1]

A BP, with many drugs on the market, has an advantage over a small company with one drug...when it comes to negotiating with governments....A BP, with bountiful assets, can accept lower prices for a certain drug and higher prices for another of their drugs...as benefits the interests of both parties in the areas of supply and pricing.

In the case of Amarin, they have too much supply, but they can't lower their prices for Vascepa, in return for increased volume...because they can't sustain a temporary loss of income from Vascepa...A BP would be better able to deal with problems of this nature.